Conference Day One - Wednesday | April 17, 2024
7:30 am Registration & Coffee
8:25 am Chair’s Opening Remarks
From Biology to Bench: Translating Fc Biology Insights to Innovate Drug Design
8:30 am Fc & its Partners: FcR’s & Complement. Interacting Biology’s Leading to Receptor Inhibitors & Improvements to IgG’s as Drugs
Synopsis
- Overview of FcRn biology and FcRn inhibitors
- FcRn and antibody half-life modulation
- Albumin as a focus for drug half-life
- Overlapping biology, complications, and opportunities
9:00 am Broad Fc effector Function Profiling for Safer & More Effective Antibody Therapeutics
Synopsis
- Complexity of inter-connected factors that influence antibody effector functions
- Implications of this complexity on both product safety and efficacy
- Strategies for mitigating the unpredictability of Fc-mediated functions in early screening through a broad and high-throughput approach
9:30 am Harnessing the Use of NK Cells with Fc Factor 8: Precision Targeting of Unwanted B-Cells Producing Factor 8 Antibodies
Synopsis
- Uncovering the potential of Fc Factor 8 to activate NK cells with precision for specific targeting
- Addressing autoimmune disorders characterized by antibodies against self-antigens
- The therapeutic potential of activating NK cells to eliminate autoimmune B-cells while minimizing collateral damage
10:00 am Preclinical Humanized Models for Assessment of Fc Receptor Pathways Targeted Therapies
Synopsis
- Recapitulating human Fc receptors expression pattern in mice
- Investigating biologics’ Fc modifications on effector function and pharmacokinetics in humanized models
- Showcase of mouse models expressing human Fc receptors as tools for translational assessment of Fc receptor-targeted therapies
10:30 am Speed Networking
Synopsis
This session is your opportunity to introduce yourself to leading experts across Fc modulation, engineering, and Fc receptor biology to establish meaningful relationships.
10:50 am Morning Break
Immuno-oncology Lessons so Far: Fc Receptor Role in IO Drug Development, Past, Present & Future to Transfer into Autoimmunity
11:15 am Innocent Until Proven Guilty: The Role of IgA in Infectious Diseases
Synopsis
- Unveiling the potent activation of myeloid cells via FcaRI
- Discussing the putative function of systemic IgA in infectious diseases
- Exploiting the potential of novel therapeutic strategies
11:45 am Fc Engineering of Antibodies for Enhanced Therapeutic Function and Safety
Synopsis
- Exploring the expression of Fc receptors in HER2+ & TNBC to guide design of Fc engineering
- Development of Fc-engineered antibodies for enhanced immune engagement
- Evaluation of NK cell activation, macrophage activation and phenotype, and in vivo efficacy of the Fc-engineered antibodies
12:15 pm Lunch & Networking
1:15 pm Next Generation Tetravalent Bispecific Antibodies for Cancer Immunotherapy
Synopsis
- Discover F-star’s unique approach to making bispecific tetravalent antibodies in the Fc
- Description of the process to produce a conditional CD137 agonist Fcab
- FS222 bispecific uses of the CD137 agonist Fcab, in combination with a PD-L1 targeting Fab
- Discuss the benefits of FS222 in being tetravalent
1:45 pm Off-the-shelf RethamTM Platelets for Assessment of Platelet Activation by Therapeutic IgG mAb Drug Candidates
Synopsis
- Platelet activation induced by IgG monoclonal antibodies can significantly increase risk for adverse thrombotic events.
- Evaluation of the potential for induction of platelet activation by therapeutic IgG mabs can be challenging, requiring fresh healthy-donor platelets, and sensitive activation readouts.
- Long-term stored RethamTM platelets that have intact FcGRIIa signaling, developed using recent breakthrough technology, can be conveniently coupled to Retham’s proprietary, technically-simple ELISA for on-demand testing to de-risk therapeutic mab candidate molecules
2:15 pm Afternoon Break, Networking, & Poster Session
Scientific Poster Session
Synopsis
Enjoy face-to-face time, share your work, and establish meaningful business relationships with many of the brightest minds, displaying scientific posters capturing the main advancements and challenges targeting Fc and Fc-mediated function.
3:15 pm Developing a Novel Cancer Therapeutic that Combines Checkpoint Blocking Function with Fc-Mediated Tumor Cell Killing
Synopsis
- Discussing antibody generation and screening
- Assessing the blocking and killing function
- Learning lessons from translational studies to support clinical development